Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer
Ursula A. Matulonis, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Dominique Berton, Jonathan S. Berek, Bente Lund, Frederik Marmé, Antonio González-Martı́n, Anna V. Tinker, Jonathan A. Ledermann, Benedict B. Benigno, Gabriel Lindahl, Nicoletta Colombo, Yong Li, Divya Gupta, Bradley J. Monk, Mansoor Raza Mirza
Topics & Concepts
MedicineInternal medicineClinical endpointNeutropeniaAdverse effectProgression-free survivalOvarian cancerOncologyPlaceboBevacizumabRandomized controlled trialMaintenance therapyPhases of clinical researchCancerClinical trialChemotherapyPathologyAlternative medicinePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentLung Cancer Research Studies